Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003
Open Access
- 22 January 2009
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 113 (4), 793-796
- https://doi.org/10.1182/blood-2008-07-172080
Abstract
The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously. The development of prognostic models in WM has been fraught by limited follow-up in current studies. Here, we update the outcome of a prospective WM trial with a median follow-up of 10 years for live patients. Of the 59 previously untreated patients who initially were observed, only 12 patients (21%) required therapy at a median follow-up of 100 months. Multivariate analysis among the 183 patients requiring therapy reaffirmed age 70 years or greater, previous nonprotocol therapy, and β-2 microglobulin (B2M) of 3 mg/dL or greater as prognostic factors. Importantly, increased serum lactate dehydrogenase (LDH) was identified as an additional independent variable, which improved risk assessment beyond the recent WM international prognostic scoring system (ISSWM). By using age, previous therapy, B2M, and LDH, we identified 3 risk groups with 8-year survival estimates of 55%, 33%, and 5% (P < .001). These data provide novel insights into factors predicting long-term outcome in WM. This trial has been registered with www.cancer.gov under ID 4852904.This publication has 19 references indexed in Scilit:
- Waldenström macroglobulinemiaBlood, 2007
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- Prognostic factors in symptomatic Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003
- Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003)Seminars in Oncology, 2003
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)Blood, 2001
- A. R.2type measure of dependence for proportional hazards modelsJournal of Nonparametric Statistics, 1999